Cardiac biomarkers are also called cardiac markers. In a condition when the heart is damaged or stressed, cardiac biomarkers (endogenous substances including enzymes, hormones, and proteins) are released into the blood. Generally, they are used to diagnose heart attack and acute coronary syndrome (ACS) or conditions associated with insufficient blood flow to the heart. Among cardiac biomarker tests, troponin is the biomarker test of choice for detecting heart damage. The test is performed with a blood sample using a needle to draw blood from a vein in the hand or arm. Troponin is elevated within a few hours of heart damage and stays elevated up to two weeks. The test performed for several hours helps diagnose a heart attack. Cardiac markers are also used in the diagnosis and risk stratification of patients with chest pain. There are other established biomarkers, such as myoglobin (test used along with troponin for early detection of heart attack) and creatinine kinase isoenzymes (also called cardiac enzyme, is linked with injury of heart muscle and detection of a second heart attack anticipated shortly after the first).
There are a number of factors that impact the growth of the cardiac biomarkers market. Some of the key factors include rise in demand for diagnostic and testing of various cardiovascular diseases, development and advancement in cardiac biomarkers, and growth in patient population suffering from cardiovascular diseases. Other key growth drivers include rise in the number of new cardiovascular cases diagnosed each year and increase in demand for disease-specific treatment in which cardiac biomarkers are used. Increasing prevalence of cardiovascular diseases is expected to boost the cardiac biomarkers market during the forecast period. According to World Health Organization, about 17.7 million people die each year from cardiovascular diseases (CVDs) and it is estimated to be the cause of 31% of the total deaths worldwide. Around 80% of all CVD deaths is due to heart attacks and strokes. However, the cardiac biomarkers market is witnessing restraints due to the development of other methods for diagnosis of cardiovascular diseases, along with high cost of procedure, lack of full proof assurance, and steep competition among existing players.
The global cardiac biomarkers market can be classified based on type, application, and geography. Based on type, the cardiac biomarkers market can be segmented into creatine kinase (CK-MB), troponins T and I, myoglobin, B-type natriuretic peptide (BNPs), N-terminal pro b-type natriuretic peptide (NT-proBNP), ischemia-modified albumin (IMA), and others. Troponins I and T are the leading revenue-generating segment in the global cardiac biomarkers market due to its prodigious specificity and ability to accurately detect the cardiac events of Acute Coronary Syndrome (ACS). In terms of application, the cardiac biomarkers market can be divided into congestive heart failure, myocardial infarction, acute coronary syndrome, atherosclerosis, and others.
Geographically, the cardiac biomarkers market can be classified into five regional markets, such as, North America (U.S. and Canada), Europe (Germany, France, U.K., etc.), Asia Pacific (Australia & New Zealand, China, Japan, India, etc.), Latin America, and Middle East & Africa. North America and Europe dominate the global cardiac biomarkers market due to increasing patient population suffering from cardiovascular diseases (angina pectoris, myocardial infraction, and others), lack of physical activity, and unhealthy diet. In addition, India, Southeast Asia, and China are the emerging markets for cardiac biomarkers due to rising incidence of coronary artery diseases in these regions. Initiatives taken by the government in Asia Pacific toward development of health care infrastructure are also expected to boost the growth of the cardiac biomarkers market in the region.
Key companies operating in the global cardiac biomarkers market are Abbott Laboratories, Beckman Coulter, Inc. bioMérieux SA, Johnson and Johnson, Olympus Corporation, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Tosoh Corporation, etc.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.